Vnitr Lek 2012, 58(7-8):93-96

Contrast nephropathy and prevention

V. Teplan1,2
1 Klinika nefrologie Transplantcentra IKEM Praha, přednosta prof. MUDr. Ondřej Viklický, CSc.
2 Subkatedra nefrologie IPVZ Praha, vedoucí prof. MUDr. Vladimír Teplan, DrSc.

Contrast-induced nephropathy (CIN) is a serious complication of radio-contrast vascular examination, mainly in high-risk patients with decreased renal function. In prevention, we have to know risk factors strongly influencing follow-up. All potential nephrotoxic drugs should be excluded. We recommend adequate intravenous hydration, supplemented individually with bicarbonate and N-acetylcystein. Studies designed to explore options in CIN prevention included trimetazidine (TMZ) belonging to cytoprotective antiischemic agents used in the treatment of angina pectoris. Trimetazidine affects reperfusion at the cellular and mitochondrial levels, and has antioxidant and metabolic activity via several mechanisms at the cellular level, that is, it shows characteristics making it a clear candidate for CIN prophylaxis. In serious cases hemofiltration could be used to help eliminate contrast solution as soon as posible. Beside serum creatinine, NGAL detected in urine may help in early diagnosis of tubular damage.

Keywords: contrast-induced nephropathy; risk patients; hydratation; trimetazidine; NGAL

Received: May 25, 2012; Published: July 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Teplan V. Contrast nephropathy and prevention. Vnitr Lek. 2012;58(7-8):93-96.
Download citation

References

  1. Šochman J Poškození ledvin kontrastními látkami. In: Teplan V et al. Akutní poškození a selhání ledvin v klinické medicíně. Praha: Grada 2010: 303-324.
  2. Zemánek D. Kontrastem navozená nefropatie. Cor Vasa 2009; 51 (Suppl 1): 69-73. Go to original source...
  3. Onbasili AO, Yeniceriglu Y, Agaoglu P et al. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures. Heart 2007; 93: 698-702. Go to original source... Go to PubMed...
  4. Mehran R, Nikolsky E Contrastinduced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 2006; 100: S11-S15. Go to original source... Go to PubMed...
  5. Lasser EC, Lyon SG, Berry CC. Reports on contrast media reactions: analysis of data from reports to the US Food and Drug Administration. Radiology 1997; 203: 605-610. Go to original source... Go to PubMed...
  6. Barrett BJ, Parfrey PS Preventing nephropathy induced by contrast medium. N Engl J Med 2006; 354: 379-386. Go to original source... Go to PubMed...
  7. McCullough PA, Wolyn R, Rocher LL et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-375. Go to original source... Go to PubMed...
  8. Katholi RE, Woods Jr WT, Tailor GJ et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis 1998; 32: 64-71. Go to original source... Go to PubMed...
  9. Zager RA, Johnson AC, Hanson SY Radiographic contrast mediainduced tubular injury: Evaluation of oxidant stress and plasma membrane integrity. Kidney Int 2003; 64: 128-139. Go to original source... Go to PubMed...
  10. Rihal CS, Textor SC, Grill DE et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-2264. Go to original source... Go to PubMed...
  11. Caldicott WJ, Hollenberg NK, Abrams HL. Characteristics of response of renal vascular bed to contrast media. Evidence of vasoconstriction induced by reninangiotensin system. Invest Radiol 1970; 5: 539-547. Go to original source... Go to PubMed...
  12. Russo D, Minutolo R, Cianciaruso B et al. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995; 6: 1451-1458. Go to original source... Go to PubMed...
  13. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older: a prospective study. Arch Intern Med 1990; 150: 1237-1242. Go to original source...
  14. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275: 1489-1494. Go to original source...
  15. Bartholomew BA, Harjai KJ, Dukkipati S et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004; 93: 1515-1519. Go to original source... Go to PubMed...
  16. Lindsay J, Canos DA, Apple S et al. Percutaneous coronary interventionassociated nephropathy foreshadows increased risk of late adverse events in patient with normal baseline serum creatinine. Catheter Cardiovasc Interv 2003; 59: 338-343. Go to original source... Go to PubMed...
  17. Brar SS, Shen AY, Jorgensen MB et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 2008; 300: 1038-1046. Go to original source... Go to PubMed...
  18. Mueller C, Buerkle G, Buettner HJ et al. Prevention of contrast mediaassociated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162: 329-336. Go to original source... Go to PubMed...
  19. Tepel M, van der Giet M, Schwarzfeld C et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180-184. Go to original source... Go to PubMed...
  20. Spargias K, Alexopoulos E, Kyrzopoulos S et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004; 110: 2837-2842. Go to original source... Go to PubMed...
  21. Khanal S, Attallah N, Smith DE et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005; 18: 843-849. Go to original source... Go to PubMed...
  22. Stone GW, Mc Cullough P, Tumlin J et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290: 2284-2291. Go to original source... Go to PubMed...
  23. Marzili M Cardioprotective effects of trimetazidine: a review. Curr Med Res Opin 2003; 19: 661-672. Go to original source... Go to PubMed...
  24. Teplan V. Možnost prevence kontrastní látkou indukované nefropatie po koronarografii trimetazidinem: příspěvek nefrologa. Cor Vasa 2011; 53: 1-3. Go to original source...
  25. Gunal AI, Celiker H, Ustundag B et al. The effect of oxidative stress inhibition with trimetazidine on the peritoneal alterations induced by hypertonic peritoneal dialysis solution. J Nephrol 2003; 16: 225-230. Go to PubMed...
  26. Aygen B, Celiker H, Dogukan A et al. The effect of trimetazidine on lipid peroxidation with end-stage renal disease. Methods Find Exp Clin Pharmacol 2008; 30: 757-760. Go to original source... Go to PubMed...
  27. Zoppo A, Faggiotto A, Redaelli L et al. Trimetazidine counteracts tacrolimus nephrotoxicity in a hypertensive liver transplant patients. Transplantation 1999; 68: 1211-1215. Go to original source... Go to PubMed...
  28. Singh D, Chopra K. Effect of trimetazidine on ischemia/reperfusion injury in rats. Pharmacol Res 2004; 50: 623-629. Go to original source... Go to PubMed...
  29. Marenzi G, Marana I, Lauri G et al. The prevention of radio contrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003; 349: 1333-1340. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.